Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome
- 1 April 2002
- journal article
- retracted article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 22 (4) , 473-482
- https://doi.org/10.1089/10799900252952262
Abstract
Elevated interleukin-10 (IL-10) and IL-6 serum levels in advanced gastrointestinal cancer patients have been shown previously. To investigate the behavior and the prognostic role of IL-10 and IL-6 serum levels in gastric and colon cancer patients undergoing surgery, we studied the relationship between these cytokine levels and surgical radicality and outcome. Seventy-eight patients with gastric or colon cancer were admitted to the study, and 50 underwent radical surgery. Cytokine serum levels were measured by ELISA the day before surgery and 16 days after surgery. Circulating levels of IL-10 and IL-6 were found to be higher in cancer patients than in controls. Both IL-10 and IL-6 serum levels were demonstrated to be able to predict likelihood to perform radical surgery. IL-10 serum levels returned to normal in all but 8 radically resected patients. These 8 patients had tumor recurrence. In contrast, IL-6 serum levels were shown to significantly decrease in all patients but not to normalize regardless of the radicality of the operation. On multivariate analysis, basal IL-10 serum levels were found to be among the variables significantly affecting the disease-free survival rate. Stepwise regression selected tumor stage, number of metastatic resected nodes, and basal IL-10 serum level as the best combination of variables for prediction of likelihood of tumor recurrence. Preoperative IL-10 serum levels may be a useful marker to predict likelihood of performing radical surgery. Abnormally high postoperative IL-10 values negatively affected disease-free survival and tumor recurrence. IL-6 serum levels were found to have a more limited prognostic role.Keywords
This publication has 24 references indexed in Scilit:
- Should Dukes' B patients receive adjuvant therapy? A statistical perspectiveSeminars in Oncology, 2001
- Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic IndicatorJournal of Interferon & Cytokine Research, 2001
- The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study: Figure 1Journal of Clinical Pathology, 2000
- ROLE OF INTERLEUKIN‐6 IN THE PATHOGENESIS OF MULTIPLE MYELOMACell Biology International, 2000
- Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsBritish Journal of Haematology, 1999
- Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neckAnnals of Surgical Oncology, 1997
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancerCancer, 1994
- Interleukin-6 in Biology and MedicinePublished by Elsevier ,1993
- Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.The Journal of Experimental Medicine, 1991